CDK4 and breast cancer: The Rb loss might partially explain the intrinsic resistance to CDK4/6 inhibitors in TNBC18; however, molecular alterations associated with the resistance to CDK4/6 inhibitors in this aggressive BC subtype have not been thoroughly elucidated yet.